AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Large Growth in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 153,264 shares, a growth of 62.0% from the February 26th total of 94,590 shares. Approximately 4.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 194,526 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, AIM ImmunoTech presently has an average rating of “Buy”.

Institutional Trading of AIM ImmunoTech

A number of large investors have recently modified their holdings of the business. DRW Securities LLC grew its holdings in shares of AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares in the last quarter. Sabby Management LLC purchased a new stake in AIM ImmunoTech in the third quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC bought a new stake in AIM ImmunoTech during the second quarter valued at approximately $87,000. Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Stock Up 1.2%

NYSEAMERICAN:AIM traded up $0.01 during trading hours on Friday, hitting $0.70. 304,630 shares of the company’s stock traded hands, compared to its average volume of 9,879,060. AIM ImmunoTech has a 52 week low of $0.61 and a 52 week high of $36.00. The business’s fifty day simple moving average is $0.98 and its two-hundred day simple moving average is $1.58. The firm has a market cap of $2.30 million, a P/E ratio of -0.03 and a beta of 1.26.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.